MassMutual Private Wealth & Trust FSB Has $308,000 Holdings in Cencora, Inc. $COR

MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 14.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,028 shares of the company’s stock after purchasing an additional 133 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Cencora were worth $308,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Range Financial Group LLC boosted its stake in Cencora by 3.3% in the second quarter. Range Financial Group LLC now owns 10,796 shares of the company’s stock worth $3,237,000 after purchasing an additional 349 shares in the last quarter. Everpar Advisors LLC increased its stake in shares of Cencora by 5.8% in the second quarter. Everpar Advisors LLC now owns 1,088 shares of the company’s stock valued at $326,000 after buying an additional 60 shares in the last quarter. Martin Capital Partners LLC raised its holdings in shares of Cencora by 205.2% in the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after buying an additional 2,544 shares during the last quarter. NBC Securities Inc. lifted its position in Cencora by 4.0% during the 2nd quarter. NBC Securities Inc. now owns 6,510 shares of the company’s stock worth $1,952,000 after buying an additional 251 shares in the last quarter. Finally, Apella Capital LLC acquired a new position in Cencora during the 2nd quarter worth about $281,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.6%

Shares of Cencora stock opened at $290.82 on Friday. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The business has a 50-day moving average of $292.52 and a two-hundred day moving average of $286.56. The company has a market capitalization of $56.38 billion, a P/E ratio of 29.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.62. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same period in the prior year, the company earned $3.34 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio is 22.63%.

Analysts Set New Price Targets

COR has been the topic of several research reports. Wells Fargo & Company upped their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Finally, Jefferies Financial Group raised their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $311.25.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the sale, the chief executive officer directly owned 42,351 shares in the company, valued at $12,455,852.61. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 65,475 shares of company stock valued at $19,080,900 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.